Advisory Research Inc Arvinas, Inc. Transaction History

Advisory Research Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$60.27 - $81.57 $264,585 - $358,092	-4,390 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$65.85 - $96.21 $1.36 Million - $1.99 Million	-20,674 Reduced 82.48%	4,390 $361,000
Q3 2021 Nov 12, 2021	BUY	$73.2 - $107.87 $130,515 - $192,332	1,783 Added 7.66%	25,064 $2.06 Million
Q2 2021 Aug 16, 2021	BUY	$60.45 - $84.26 $1.41 Million - $1.96 Million	23,281 New	23,281 $1.79 Million
Q2 2020 Aug 13, 2020	SELL	$29.88 - $56.74 $531,804 - $1.01 Million	-17,798 Closed	0 $0

Q1 2020 May 12, 2020	SELL	$33.0 - $54.5 $435,732 - $719,618	-13,204 Reduced 42.59%	17,798 $717,000
Q4 2019 Feb 11, 2020	SELL	$15.39 - $44.38 $107,406 - $309,728	-6,979 Reduced 18.37%	31,002 $1.27 Million
Q3 2019 Nov 12, 2019	BUY	$21.55 - $27.61 $189,704 - $243,050	8,803 Added 30.17%	37,981 $818,000
Q2 2019 Aug 14, 2019	BUY	$15.96 - $23.8 $465,680 - $694,436	29,178 New	29,178 $642,000

234

64.9M

119K

94.2K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.32B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

Stay updated on Advisory Research Inc with notifications on news.